Education
About Us
Working with TipRanks
Follow Us
Hansa Biopharma (DE:24H)
FRANKFURT:24H
Earnings Data
Report Date
Jul 17, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.17Last Year’s EPS
-0.3Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Apr 24, 2025
|% Change Since: 18.19%
|Next Earnings Date:Jul 17, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted strong revenue growth and strategic progress in the pipeline and reimbursement expansion. However, concerns regarding the sudden CEO change, temporary study delays, and cash runway limitations were also significant. The sentiment reflects a balanced outlook with both positive advancements and notable challenges.Company Guidance
During Hansa Biopharma's Q1 2025 earnings call, the company reported total revenue of SEK 66.3 million, with IDEFIRIX sales contributing SEK 65.7 million, marking a 39% increase in product sales from the previous quarter. They announced the completion of patient enrollment in the PAES Phase 3 study in Europe, which is crucial for full marketing authorization by EMA in 2026. The company is also advancing its pipeline, including a proposed clinical trial for HNSA-5487 in myasthenia gravis. Key upcoming catalysts in 2025 include data from multiple trials, such as the Phase 3 GOOD-IDES-02 study and the U.S. Phase 3 ConfIdeS study in kidney transplantation. Hansa also noted an 18% increase in total revenue compared to Q1 2024 and emphasized continued efforts to expand IDEFIRIX's market access, now reimbursed in 18 countries. The company has undertaken restructuring activities to reduce SG&A and R&D expenses, improving the operating loss by 71% compared to the previous year.Significant Revenue Growth
In Q1 2025, total revenue reached SEK 66.3 million, with a 39% increase in product sales from the previous quarter.
Pipeline Progress
Completion of enrollment in the PAES Phase 3 study in Europe and positive regulatory interactions with BfArM regarding HNSA-5487 for myasthenia gravis.
Expansion and Reimbursement
Secured reimbursement for Idefirix in three additional European markets, totaling 18 countries, including the largest five European markets.
Long-term Data and Publications
Sustained positive outcomes from five-year data on imlifidase-treated kidney transplant patients, with a 90% patient survival rate and an 82% graft survival rate.
Financial Improvements
Operating loss improved by 71% compared to Q1 2024, driven by increased sales and expense reduction.
---
DE:24H Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
DE:24H Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 24, 2025 | €1.96 | €2.34 | +19.41% |
Feb 06, 2025 | €2.86 | €2.18 | -23.76% |
Oct 17, 2024 | €3.50 | €3.42 | -2.51% |
Jul 18, 2024 | €4.05 | €3.36 | -17.14% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Hansa Biopharma (DE:24H) report earnings?
Hansa Biopharma (DE:24H) is schdueled to report earning on Jul 17, 2025, TBA Not Confirmed.
What is Hansa Biopharma (DE:24H) earnings time?
Hansa Biopharma (DE:24H) earnings time is at Jul 17, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Hansa Biopharma stock?
The P/E ratio of Hansa Biopharma AB is N/A.
What is DE:24H EPS forecast?
DE:24H EPS forecast for the fiscal quarter 2025 (Q2) is -0.17.
---